SAN DIEGO & REHOVOT, Israel, April 04, 2024 Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced data from a pilot study demonstrating the potential of a simple PCR assay based on EpiCheck® technology to accurately differentiate between small cell lung cancer (SCLC) subtypes. The Company is presenting the data in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, April 5-10
Nucleix Receives Reimbursement for Bladder EpiCheck® in the Netherlands lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
Epigenetic Test May Rule Out High-Grade UTUC renalandurologynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from renalandurologynews.com Daily Mail and Mail on Sunday newspapers.
Non-Invasive Liquid Biopsy Market to Reach $9.47 Billion - Global Market Analysis & Forecasts to 203 pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.